AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Praxis Precision Medicines Sees 20% Surge on Positive Interim EMBOLD Trial Data
ByAinvest
Friday, Dec 5, 2025 6:46 am ET1min read
Praxis Precision Medicines' shares surged 20% in premarket trading after a Data Monitoring Committee recommended early stopping of the EMBOLD trial of Relutrigine based on interim efficacy results. The company plans to share topline results at the American Epilepsy Society Annual Meeting on December 6, 2025. The FDA meeting and NDA filing timing will be decided after the meeting. The stock closed yesterday at $189.97, up 2.05%, and is trading 23.18% higher at $234 in the pre-market.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet